Yoltech Therapeutics

Based in Shanghai, China, and founded in 2021, Yoltech Therapeutics is a biotech company committed to developing gene-editing drugs against hereditary diseases and cardiovascular diseases. The company's founder, Dr. Yuxuan Wu, graduated from East China Normal University. From 2015 to 2018, he developed and optimized the gene-editing system based on CRISPR-Cas on hematopoietic stem cells (HSCs).

Meanwhile, in April and June 2022, the Company completed the patent application for its self-developed base editor and the patent application for Cas protein and novel Lnp delivery, respectively. In November 2023, it closed a round of series A+ funding. In September 2025, Yoltech Therapeutics closed series B funding led by new investor CICC Capital, with participation from new investors Green Pine Capital Partners, Tianjin Venture Capital and Beijing Xinneng Venture Capital, and returning investors K2VC, Grand Flight Investment and Decheng Capital. The company focuses on the development of mRNA drugs and gene editing drugs by improving mRNA production platforms and lipid nanocarrier assembly processes through CRISPR, base editing and other gene editing tools.

The current pipeline of products in development includes LNP in vitro delivery of gene edited drugs for metabolic diseases (familial hypercholesterolemia, etc. ), genetic diseases (primary hyperoxaluria, etc. ), and infectious diseases (hepatitis B, etc. ).

The company generates revenue from providing gene-editing drugs.